Expert Opinion on Orphan Drugs

Scope & Guideline

Transforming challenges into solutions for rare diseases.

Introduction

Explore the comprehensive scope of Expert Opinion on Orphan Drugs through our detailed guidelines, including its aims and scope. Stay updated with trending and emerging topics, and delve into declining areas to understand shifts in academic interest. Our guidelines also showcase highly cited topics, featuring influential research making a significant impact. Additionally, discover the latest published papers and those with high citation counts, offering a snapshot of current scholarly conversations. Use these guidelines to explore Expert Opinion on Orphan Drugs in depth and align your research initiatives with current academic trends.
LanguageEnglish
ISSN2167-8707
PublisherTAYLOR & FRANCIS LTD
Support Open AccessNo
CountryUnited Kingdom
TypeJournal
Convergefrom 2013 to 2024
AbbreviationEXPERT OPIN ORPHAN D / Exp. Opin. Orphan Drugs
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND

Aims and Scopes

The journal 'Expert Opinion on Orphan Drugs' focuses on the dissemination of knowledge regarding orphan drugs and rare diseases, aiming to improve treatment options and patient outcomes.
  1. Orphan Drug Research:
    The journal emphasizes the development, approval, and clinical use of orphan drugs, which are medications designed to treat rare diseases that affect small patient populations.
  2. Clinical Management of Rare Diseases:
    It covers clinical practices, management strategies, and therapeutic interventions in the treatment of various rare diseases, providing insights into effective patient care.
  3. Health Technology Assessments:
    The journal investigates the economic aspects of orphan drug therapies, including cost-effectiveness analyses, pricing negotiations, and reimbursement policies associated with rare disease treatments.
  4. Patient Experience and Quality of Life:
    Research is dedicated to understanding the impact of rare diseases on patients' quality of life, including studies on patient-reported outcomes and symptom management.
  5. Genetic and Molecular Insights:
    The journal publishes findings on the genetic and molecular underpinnings of rare diseases, contributing to the understanding of pathogenesis and therapeutic targets.
The journal has seen a rise in focus on several key themes, reflecting current trends and emerging areas of interest in orphan drug research and rare disease management.
  1. Innovative Therapeutic Strategies:
    There is a growing emphasis on novel therapies and treatment modalities for rare diseases, highlighting advances in drug development and innovative approaches to patient care.
  2. Real-World Evidence and Registries:
    Recent publications are increasingly focusing on real-world data and registry-based research, which provide valuable insights into treatment efficacy and patient experiences in diverse populations.
  3. Genetic Testing and Personalized Medicine:
    The rise in articles discussing genetic testing and personalized approaches underscores the importance of tailoring treatments based on individual genetic profiles, enhancing therapeutic outcomes.
  4. Access and Affordability of Orphan Drugs:
    There is an emerging trend focusing on patient access to orphan drugs, addressing the challenges of affordability and the impact of health policies on drug availability.
  5. Patient-Centric Research:
    Research centered on patient experiences, outcomes, and quality of life is increasingly prioritized, reflecting a broader trend towards patient involvement in the management of rare diseases.

Declining or Waning

Over recent years, certain themes within the journal have shown a decline in frequency and emphasis, indicating a potential shift in research focus or changing priorities in the field.
  1. Traditional Chemotherapy Approaches:
    There appears to be a waning interest in discussing traditional chemotherapy methods for rare cancers, as newer targeted therapies and personalized medicine approaches are gaining traction.
  2. Generalized Discussions on Rare Diseases:
    Broad discussions that do not focus on specific therapies or patient outcomes are becoming less common, as the journal increasingly prioritizes targeted research and innovative therapies.
  3. Historical Analyses of Drug Approvals:
    While previously common, retrospective analyses of orphan drug approvals over extended periods are less frequent, suggesting a shift toward more current and forward-looking research.

Similar Journals

Journal of Neuromuscular Diseases

Driving progress in the understanding of neuromuscular disorders.
Publisher: IOS PRESSISSN: 2214-3599Frequency: 1 issue/year

Journal of Neuromuscular Diseases, published by IOS PRESS, is a leading platform dedicated to advancing the field of neurology and neuromuscular research. With a focus on delivering high-quality, peer-reviewed content, this journal aims to foster knowledge sharing and collaboration among researchers, clinicians, and healthcare professionals dealing with neuromuscular disorders. The journal boasts a commendable impact factor within its respective categories, achieving Q2 rankings in both Neurology and Clinical Neurology as of 2023. Spanning from its inception in 2014 to the anticipated convergence in 2024, it is recognized for its contributions to critical discussions in the field, evidenced by its rankings of #145 out of 400 in clinical neurology and #75 out of 192 in neuroscience. As an open access journal, it facilitates wider accessibility of research findings, catering to an audience eager for innovative approaches and developments. Set against the backdrop of the vibrant academic scene in the Netherlands, the Journal of Neuromuscular Diseases serves as an essential resource for driving forward the boundaries of knowledge in neuromuscular-related conditions.

Therapeutic Advances in Allergy and Rhinology

Exploring new frontiers in nasal health and allergy management.
Publisher: SAGE PUBLICATIONS INCISSN: 2753-4030Frequency: 1 issue/year

Therapeutic Advances in Allergy and Rhinology, published by SAGE Publications Inc, is an esteemed journal that focuses on advancing the fields of allergy and rhinology through innovative and impactful research. As an Open Access journal, it provides a platform for researchers, clinicians, and students to share significant findings and therapeutic developments aimed at improving patient outcomes related to allergic conditions and nasal disorders. The journal aims to publish high-quality peer-reviewed articles, reviews, and case studies that contribute to a deeper understanding of the pathophysiology and management of allergies and rhinological conditions. By fostering collaborative dialogue across various disciplines, Therapeutic Advances in Allergy and Rhinology plays a crucial role in enhancing clinical practice and guiding future research in this vital area of health. With an ISSN of 2753-4030, the journal continues to establish itself as a key resource for anyone involved in allergy and rhinology research and practice.

Internal Medicine

Exploring Innovations in Internal Medicine Research
Publisher: JAPAN SOC INTERNAL MEDICINEISSN: 0918-2918Frequency: 12 issues/year

Internal Medicine is a distinguished peer-reviewed journal published by the Japan Society of Internal Medicine, focusing on the nuanced field of internal medicine. Since its inception in 1974 and with a commitment to advancing medical knowledge, the journal has evolved remarkably, aiming to disseminate high-quality research that contributes to the understanding and treatment of internal diseases. Operating from Tokyo, Japan, it provides an intellectual platform for researchers and clinicians to publish original articles, reviews, and case studies that address various aspects of internal medicine. The journal currently holds a ranking in the Q3 quartile for both Internal Medicine and miscellaneous Medicine categories as of 2023, signifying its growing influence in the medical community. Although not an open-access journal, it remains accessible to a wide audience through institutional subscriptions, enhancing its reach among professionals and students alike. With its commitment to excellence, Internal Medicine serves as an essential resource for those seeking the latest developments and research within this vital medical field.

Current Rheumatology Reviews

Shaping the future of rheumatology through rigorous reviews.
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1573-3971Frequency: 3 issues/year

Current Rheumatology Reviews is an esteemed journal dedicated to publishing comprehensive reviews on advancements in the field of rheumatology. Established by Bentham Science Publishers, this journal has become a vital resource for researchers, clinicians, and students seeking to stay abreast of the latest developments and therapeutic strategies from 2006 to 2024. Located in the United Arab Emirates, it caters to a global audience, delivering insights that have been pivotal in shaping clinical practices. With an impact factor reflective of its Q3 status in Rheumatology by 2023, the journal ranks #46 out of 73 in the Scopus database, positioning it in the 37th percentile in the discipline. Although it operates without open access, its high-quality content ensures that each article undergoes rigorous peer review, making the Current Rheumatology Reviews a trusted platform for disseminating critical research findings and reviews that drive forward the understanding and treatment of rheumatic diseases.

Intractable & Rare Diseases Research

Advancing Knowledge for the Uncommon.
Publisher: INT RESEARCH & COOPERATION ASSOC BIO & SOCIO-SCIENCES ADVANCEMENTISSN: 2186-3644Frequency: 4 issues/year

Intractable & Rare Diseases Research is a pioneering journal dedicated to advancing the understanding and treatment of rare and intractable diseases. Published by INT RESEARCH & COOPERATION ASSOC BIO & SOCIO-SCIENCES ADVANCEMENT in Japan, this esteemed journal serves as a critical platform for researchers, clinicians, and healthcare professionals to share groundbreaking findings and developments in the field. With its established Scopus ranking of #238 out of 636 in the General Medicine category, placing it in the 62nd percentile, and its classification in the Q3 quartile for 2023, it is recognized as a significant contributor to the literature on rare diseases. Operating without an open-access model, the journal ensures high-quality content cultivated through rigorous peer-review processes. Through its scope spanning from 2012 to 2024, the journal aspires to bridge gaps in knowledge and foster collaboration among interdisciplinary researchers, ultimately aiming to improve patient outcomes and enhance public health concerning these challenging conditions.

BMC Rheumatology

Championing excellence in the study of rheumatology.
Publisher: SPRINGERNATUREISSN: Frequency: 1 issue/year

BMC Rheumatology is a vital open-access journal that has been disseminating high-quality research in the field of rheumatology since its inception in 2017. Published by Springer Nature, this journal provides a platform for original research, reviews, and clinical studies that advance the understanding and treatment of rheumatic diseases. With a commendable impact factor and ranked in the second quartile (Q2) for Rheumatology as of 2023, BMC Rheumatology exemplifies expertise, contributing significantly to the medical community's dialogue. Researchers, professionals, and students will find valuable insights within its pages, as it caters to a diverse audience through its commitment to open-access publishing, facilitating knowledge sharing without barriers. Based in the United Kingdom and indexed in Scopus, the journal continues to thrive with a steady convergence of academic excellence through 2024, making it an indispensable resource for those dedicated to advancing rheumatological science.

JOURNAL OF RHEUMATOLOGY

Exploring the Complexities of Rheumatic Diseases
Publisher: J RHEUMATOL PUBL COISSN: 0315-162XFrequency: 12 issues/year

JOURNAL OF RHEUMATOLOGY, published by the J Rheumatol Publ Co, stands as a distinguished platform within the fields of rheumatology and immunology since its inception in 1974. With an impressive impact evidenced by its 2023 rankings—Q1 in Rheumatology and Q2 in both Immunology and Allergy—the journal has secured its position as a vital resource for researchers and practitioners alike. The journal is dedicated to advancing clinical and experimental knowledge in the pathogenesis, diagnosis, and management of rheumatic diseases, providing a rich repository of peer-reviewed articles that drive innovation in treatment protocols and patient care. Although it operates under a subscription model, the journal remains accessible to a broad audience committed to advancing their understanding of these critical areas. Located in Toronto, Canada, it continues to attract contributions from leading experts globally, making it an essential read for anyone keen on staying at the forefront of rheumatological research and practice.

Journal of Rheumatic Diseases

Advancing knowledge in rheumatology for a healthier tomorrow.
Publisher: KOREAN COLL RHEUMATOLOGYISSN: 2093-940XFrequency: 4 issues/year

Journal of Rheumatic Diseases, published by the Korean College of Rheumatology, stands as a pivotal platform in the field of rheumatology, contributing significantly to the advancement of knowledge and clinical practice since its inception. With an impact factor reflecting its esteemed position in the academic community, this open-access journal promotes accessibility to high-quality research, ensuring that groundbreaking discoveries are reachable to all stakeholders in the realm of rheumatic diseases. The journal has maintained its commitment to quality, evidenced by its ranking in the Q3 category for Rheumatology in 2023, and its presence among the top quartiles of medical research. Focusing on innovative therapeutic approaches, emerging diagnostic techniques, and comprehensive reviews, the Journal of Rheumatic Diseases seeks to foster collaboration and dialogue among researchers, clinicians, and students alike. For accessibility, the journal offers numerous articles since its transition to open access in 2017, thereby facilitating research dissemination across the globe. As it converges over the years from 2019 to 2024, the journal promises to be instrumental in shaping the future of rheumatic disease research, inviting contributions that inspire new frontiers in this essential field.

JOURNAL OF ENDOCRINOLOGY

Transforming Knowledge into Practice in Endocrinology
Publisher: BIOSCIENTIFICA LTDISSN: 0022-0795Frequency: 12 issues/year

JOURNAL OF ENDOCRINOLOGY, established in 1946 and published by BIOSCIENTIFICA LTD, stands as a premier scholarly outlet in the field of endocrinology, diabetes, and metabolism. With an impressive H-Index reflecting its significant contribution to the literature, this journal maintains a strong presence in academic circles, evidenced by its Q1 ranking in the 2023 Scopus categories for both Endocrinology and Diabetes and Metabolism. With its targeted scope serving a global audience of researchers, professionals, and students, it provides a vital platform for disseminating innovative research findings and advancing the scientific understanding of endocrine systems. As we approach its convergence year of 2024, JOURNAL OF ENDOCRINOLOGY remains committed to publishing high-quality, peer-reviewed articles that explore cutting-edge developments in the field, thereby impacting clinical practices and guiding future research directions.

CARDIOVASCULAR DRUGS AND THERAPY

Exploring innovative therapies for a healthier heart.
Publisher: SPRINGERISSN: 0920-3206Frequency: 6 issues/year

CARDIOVASCULAR DRUGS AND THERAPY, published by Springer, is a premier journal dedicated to the latest advances in cardiovascular pharmacology and therapeutics. With a significant impact factor and esteemed rankings in cardiology and pharmacology, this journal is positioned in the top quartile categories, reflecting its influence and contribution to the field. Since its inception in 1987, the journal has served an international audience, providing a platform for researchers and practitioners to publish high-quality original research, critical reviews, and innovative clinical studies that address pressing issues in cardiovascular health. The journal's rigorous peer-review process ensures the utmost scholarly merit, making it an essential resource for professionals aiming to stay at the forefront of cardiovascular drug research and therapy. While not an open-access publication, it is widely available through institutional subscriptions, enhancing its reach within the global community of cardiology researchers and practitioners. Located in the Netherlands, CARDIOVASCULAR DRUGS AND THERAPY continues to play a vital role in advancing our understanding of cardiovascular diseases and the pharmacological solutions available to combat them.